Hikma Pharmaceuticals Plc Directorate Change (2804W)
November 06 2014 - 2:02AM
UK Regulatory
TIDMHIK
RNS Number : 2804W
Hikma Pharmaceuticals Plc
06 November 2014
Board Appointment - Dr Pamela Kirby
London, 6 November 2014 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) (OTC: HKMPY) ("Hikma"), the FTSE 250 pharmaceuticals
company, is today announcing the appointment of Dr Pamela Kirby as
an independent non-executive director of the Company with effect
from 1 December 2014. Dr Kirby will join the Audit, Remuneration
and Compliance, Responsibility and Ethics (CRE) Committees.
Said Darwazah, Chairman and Chief Executive, said: "I am
delighted that Dr Kirby has agreed to join our Board. She brings a
wealth of pharmaceutical, international, strategic, and listed
company experience. She has a strong track record from her senior
executive and board-level roles, and complements our culture and
style perfectly. I am confident that she will enhance the
capabilities of the Board, and that we are now in an even stronger
position to lead our company going forward."
Dr Pamela Kirby
Dr Pamela Kirby was CEO of Quintiles Transnational Corp and has
held senior executive positions in F Hoffmann-La Roche Ltd and
AstraZeneca plc. Dr Kirby has chaired Oxford Immunotec Ltd and was
senior independent director of Informa plc. Dr Kirby has previously
held non-executive director positions with Smith & Nephew plc,
Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals
Corp.
Dr Kirby is chairman of Scynexis Inc and a non-executive
director of DCC plc and Victrex plc.
Dr Kirby holds a first-class Bachelor of Science degree in
Pharmacology and a PhD in Clinical Pharmacology from the University
of London.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, Vice President for Investor Relations +44 (0)20 7399 2760
Financial Dynamics +44 (0)20 3727 1000
Matthew Cole & Ben Atwell
Notes to Editors:
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2013, Hikma achieved
revenues of $1,365 million and profit attributable to shareholders
of $212 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUGGRCGUPCGMA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024